These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36582222)

  • 1. Enhanced Spike-specific, but attenuated Nucleocapsid-specific T cell responses upon SARS-CoV-2 breakthrough versus non-breakthrough infections.
    Ahmed MIM; Diepers P; Janke C; Plank M; Eser TM; Rubio-Acero R; Fuchs A; Baranov O; Castelletti N; Kroidl I; Olbrich L; Bauer B; Wang D; Prelog M; Liese JG; Reinkemeyer C; Hoelscher M; Steininger P; Überla K; Wieser A; Geldmacher C
    Front Immunol; 2022; 13():1026473. PubMed ID: 36582222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.
    Datwani S; Kalikawe R; Waterworth R; Mwimanzi FM; Liang R; Sang Y; Lapointe HR; Cheung PK; Omondi FH; Duncan MC; Barad E; Speckmaier S; Moran-Garcia N; DeMarco ML; Hedgcock M; Costiniuk CT; Hull M; Harris M; Romney MG; Montaner JSG; Brumme ZL; Brockman MA
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study.
    Kared H; Jyssum I; Alirezaylavasani A; Egner IM; The Tran T; Tietze L; Lund KP; Tveter AT; Provan SA; Ørbo H; Haavardsholm EA; Vaage JT; Jørgensen K; Syversen SW; Lund-Johansen F; Goll GL; Munthe LA
    Front Immunol; 2024; 15():1296273. PubMed ID: 38455062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population.
    Gromowski GD; Cincotta CM; Mayer S; King J; Swafford I; McCracken MK; Coleman D; Enoch J; Storme C; Darden J; Peel S; Epperson D; McKee K; Currier JR; Okulicz J; Paquin-Proulx D; Cowden J; Peachman K
    EBioMedicine; 2023 Aug; 94():104683. PubMed ID: 37413891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dominant CD8
    Taus E; Hofmann C; Ibarrondo FJ; Hausner MA; Fulcher JA; Krogstad P; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
    Front Immunol; 2022; 13():835830. PubMed ID: 35273611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G.
    Anderson M; Stec M; Gosha A; Mohammad T; Boler M; Tojo Suarez R; Behun D; Landay A; Cloherty G; Moy J
    J Infect Dis; 2022 Nov; 226(11):1934-1942. PubMed ID: 36263799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spike Mutation Profiles Associated With SARS-CoV-2 Breakthrough Infections in Delta Emerging and Predominant Time Periods in British Columbia, Canada.
    Fibke CD; Joffres Y; Tyson JR; Colijn C; Janjua NZ; Fjell C; Prystajecky N; Jassem A; Sbihi H
    Front Public Health; 2022; 10():915363. PubMed ID: 35859775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire.
    Tarke A; Ramezani-Rad P; Alves Pereira Neto T; Lee Y; Silva-Moraes V; Goodwin B; Bloom N; Siddiqui L; Avalos L; Frazier A; Zhang Z; da Silva Antunes R; Dan J; Crotty S; Grifoni A; Sette A
    Cell Rep Med; 2024 Jun; 5(6):101583. PubMed ID: 38781962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
    Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D;
    J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study.
    Chia PY; Ong SWX; Chiew CJ; Ang LW; Chavatte JM; Mak TM; Cui L; Kalimuddin S; Chia WN; Tan CW; Chai LYA; Tan SY; Zheng S; Lin RTP; Wang L; Leo YS; Lee VJ; Lye DC; Young BE
    Clin Microbiol Infect; 2022 Apr; 28(4):612.e1-612.e7. PubMed ID: 34826623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of anti-nucleocapsid antibody assays for the detection of SARS-CoV-2 Omicron vaccine breakthroughs after various intervals since the infection.
    Springer DN; Reuberger E; Borsodi C; Puchhammer-Stöckl E; Weseslindtner L
    J Med Virol; 2023 Nov; 95(11):e29229. PubMed ID: 37966995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination.
    Paniskaki K; Anft M; Meister TL; Marheinecke C; Pfaender S; Skrzypczyk S; Seibert FS; Thieme CJ; Konik MJ; Dolff S; Anastasiou O; Holzer B; Dittmer U; Queren C; Fricke L; Rohn H; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
    Front Immunol; 2022; 13():816220. PubMed ID: 35145522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein.
    Castro JT; Azevedo P; Fumagalli MJ; Hojo-Souza NS; Salazar N; Almeida GG; Oliveira LI; Faustino L; Antonelli LR; Marçal TG; Augusto M; Valiate B; Fiorini A; Rattis B; Ramos SG; Piccin M; Nonato OC; Benevides L; Magalhães R; Cassaro B; Burle G; Doro D; Kalil J; Durigon E; Salazar A; Caballero O; Santiago H; Machado A; Silva JS; da Fonseca F; Fernandes AP; Teixeira SR; Gazzinelli RT
    Nat Commun; 2022 Aug; 13(1):4831. PubMed ID: 35977933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
    Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
    Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants.
    Koutsakos M; Lee WS; Reynaldi A; Tan HX; Gare G; Kinsella P; Liew KC; Taiaroa G; Williamson DA; Kent HE; Stadler E; Cromer D; Khoury DS; Wheatley AK; Juno JA; Davenport MP; Kent SJ
    Immunity; 2022 Jul; 55(7):1316-1326.e4. PubMed ID: 35690062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection.
    Ahmed MIM; Einhauser S; Peiter C; Senninger A; Baranov O; Eser TM; Huth M; Olbrich L; Castelletti N; Rubio-Acero R; Carnell G; Heeney J; Kroidl I; Held K; Wieser A; Janke C; Hoelscher M; Hasenauer J; Wagner R; Geldmacher C;
    iScience; 2024 Jun; 27(6):110138. PubMed ID: 38974469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.